semaglutide and platelets Synergy of dual pathway inhibition on platelet activation. Combining Key Considerations for Semaglutide Use
Description
Clinical data show average weight loss of 515% of body weight over 612 months with dual therapy, though individual results vary
Current clinical evidence supports continuous use over cycling for most patients seeking sustained weight loss
Therefore, the combination of abatacept with TNF-blockers including HUMIRA is not recommended [see Drug Interactions (7.2)]
GLP-1 in mentioned in our post about hormones implicated in weight control
